Source comparison
MOTS-c Support Longevity Optimization: Comparison Analysis
Primary pathway AMPK activation, mitochondrial biogenesis AMPK activation, complex I inhibition NAD+ restoration, sirtuin activation MOTS-c and metformin share AMPK pathway but differ in mitochondrial specificity; NAD+ precursors work upstream Human lifespan d
This comparison does not assign a generated winner or score.
- Primary pathway
- AMPK activation, mitochondrial biogenesis
- AMPK activation, complex I inhibition
- NAD+ restoration, sirtuin activation
- MOTS-c and metformin share AMPK pathway but differ in mitochondrial specificity; NAD+ precursors work upstream
- Human lifespan data
- None. Preclinical only
- Observational (diabetics live longer on metformin vs other drugs)
- None. Surrogate biomarkers only
- No longevity compound has direct human lifespan trial data
- Metabolic biomarker changes
- 8% glucose reduction, 12% HOMA-IR improvement (small trial)
- 10–15% glucose reduction, proven cardiovascular benefit
- Variable. NAD+ increases 40–90% but limited metabolic endpoint data
- Metformin has strongest clinical metabolic evidence; MOTS-c shows promise but limited trial volume
- Administration requirement
- Injectable (subcutaneous), 3x weekly minimum
- Oral, daily
- Injectable requirement reduces adherence vs oral alternatives
- Side effect profile
- Injection site reactions (30%), otherwise minimal in trials
- GI distress (20–30%), lactic acidosis risk (rare)
- Generally well-tolerated, occasional flushing
- MOTS-c tolerability appears favorable but sample size too small for rare event detection
- Cost (research-grade, monthly)
- $180–$320
- $4–$15 (generic metformin)
- $40–$120
- Metformin dramatically more cost-effective for metabolic benefit